Adicet Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adicet Bio, Inc. (ACET) on April 14, 2025, covering events occurring on April 14, 2025, and April 16, 2025. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Carl L. Gordon, Ph.D., resigned from the Board of Directors and the Compensation Committee, effective April 17, 2025. The resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- Appointment: Michael Grissinger was appointed to the Board of Directors and the Compensation Committee, effective April 17, 2025, to fill the vacancy left by Dr. Gordon.
- Term: Mr. Grissinger will serve as a Class II director until the 2026 annual meeting of stockholders.
- Independence: The Board determined Mr. Grissinger is independent under Nasdaq listing standards.
Compensation and Governance Details
- Compensation: Mr. Grissinger will receive cash compensation in accordance with the Company's Non-Employee Director Compensation Policy.
- Stock Option Grant: Mr. Grissinger was granted an option to purchase 70,200 shares of common stock. The exercise price equals the closing price on April 17, 2025. The shares vest in 36 equal monthly installments commencing April 17, 2025, subject to continued service.
- Agreements: Mr. Grissinger has entered into a standard indemnification agreement. No transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Michael Grissinger, against Nasdaq listing standards.
- Confirm the vesting schedule and exercise price of the 70,200 share option granted to Mr. Grissinger.
- Review the press release (Exhibit 99.1) for additional context on the Board's strategic direction following the personnel change.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.